Henlius finds elixir in first profits, scraps A-share IPO
The drug maker said last week it will halt plans for a second listing on China’s STAR Market, the same day it announced its first-ever interim profit since its 2019…
Recent Articles
RELATED ARTICLES
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
‘Sing! China’ flames out, leaving STAR CM in the dark
6698.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
